Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised
Executive Summary
Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests
You may also be interested in...
Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Roche/GlaxoSmithKline's aggressive pricing strategy for Boniva injection relative to the oral formulation indicates the firms feel Medicare Part B is a more advantageous reimbursement environment than Part D
Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Roche/GlaxoSmithKline's aggressive pricing strategy for Boniva injection relative to the oral formulation indicates the firms feel Medicare Part B is a more advantageous reimbursement environment than Part D
Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector
Novartis will continue to focus on the cardiovascular-metabolic segment in the near term with filings planned for new diabetes and hypertension therapies and line-extensions for its existing agents